Merck & Co. Overview
- Year Founded
-
1891
- Status
-
Public
- Employees
-
75,000
- Stock Symbol
-
MRK
- Investments
-
106
- Share Price
-
$78.28
- (As of Tuesday Closing)
Merck & Co. General Information
Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact Information
Website
www.merck.comCorporate Office
- 126 East Lincoln Avenue
- PO Box 2000
- Rahway, NJ 07065
- United States
Corporate Office
- 126 East Lincoln Avenue
- PO Box 2000
- Rahway, NJ 07065
- United States
Merck & Co. Timeline
Merck & Co. Stock Performance
As of 17-Jun-2025, Merck & Co.’s stock price is $78.28. Its current market cap is $197B with 2.51B shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $78.28 | $80.96 | $73.31 - $134.63 | $197B | 2.51B | 16.2M | $6.89 |
Merck & Co. Financials Summary
As of 31-Mar-2025, Merck & Co. has a trailing 12-month revenue of $63.9B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 250,218,013 | 275,244,154 | 302,399,197 | 300,538,183 |
| Revenue | 63,922,000 | 64,168,000 | 60,115,000 | 59,283,000 |
| EBITDA | 25,613,000 | 25,291,000 | 6,542,000 | 21,158,000 |
| Net Income | 17,434,000 | 17,117,000 | 365,000 | 14,519,000 |
| Total Assets | 115,122,000 | 117,106,000 | 106,675,000 | 109,160,000 |
| Total Debt | 34,844,000 | 37,111,000 | 35,055,000 | 30,691,000 |
Merck & Co. Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Merck & Co. Comparisons
Industry
Financing
Details
Merck & Co. Competitors (42)
One of Merck & Co.’s 42 competitors is GSK, a Corporation company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GSK | Corporation | London, United Kingdom | ||||
| Pfizer (Pharmaceuticals) | Corporation | New York, NY | ||||
| AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
Merck & Co. Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Merck & Co. Patents
Merck & Co. Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250161420-A1 | Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease | Pending | 16-Nov-2023 | ||
| US-20250152658-A1 | Cyclic peptide for trapping interleukin-1 beta | Pending | 14-Nov-2023 | ||
| US-20250154173-A1 | Ripk1 inhibitors and methods of use | Pending | 02-Nov-2023 | ||
| US-20250136910-A1 | Devices for use as blood brain barrier models | Pending | 25-Oct-2023 | ||
| US-20250136615-A1 | Small molecule inhibitors of kras proteins | Pending | 20-Oct-2023 | C07D498/22 |
Merck & Co. Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Merck & Co. Investments & Acquisitions (106)
Merck & Co.’s most recent deal was a Corporate Asset Purchase with WuXi (15,520 Square Meter Vaccine Plant in Dundalk, Ireland) for . The deal was made on 06-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| WuXi (15,520 Square Meter Vaccine Plant in Dundalk, Ireland) | 06-Jan-2025 | Corporate Asset Purchase | Buildings and Property | ||
| WuXi Biologics (Vaccine Facility in Ireland) | 06-Jan-2025 | Corporate Asset Purchase | Medical Supplies | ||
| LaNova Medicines (Global Rights for Cancer Bispecific Antibody LM-299) | 20-Dec-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Personalis | 19-Dec-2024 | PIPE | Drug Discovery | ||
| Aktis Oncology | 20-Sep-2024 | Early Stage VC | Drug Discovery |
Merck & Co. ESG
Risk Overview
Risk Rating
Updated June, 03, 2025
18.81 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Merck & Co. Exits (37)
Merck & Co.’s most recent exit was on 21-Dec-2023 from Evaxion. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Evaxion | 21-Dec-2023 | Completed |
|
||
| Kelun Biotech | 29-Dec-2022 | Completed |
|
||
| Ponea Health | 01-Sep-2022 | Completed |
|
||
| Syapse | 28-Jul-2022 | Completed |
|
||
| Vence | 16-Mar-2022 | Later Stage VC | Completed |
|
Merck & Co. Affiliates
Subsidiaries (11)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Caraway Therapeutics | Cambridge, MA | 2018 | |
| Merck Animal Health Ventures | Rahway, NJ | 2017 | |
| MRL Ventures Fund | Cambridge, MA | 2015 | |
| Peloton Therapeutics | Dallas, TX | 2011 | |
| Merck Global Health Innovation Fund | Rahway, NJ | 2010 |
Merck & Co. FAQs
-
When was Merck & Co. founded?
Merck & Co. was founded in 1891.
-
Where is Merck & Co. headquartered?
Merck & Co. is headquartered in Rahway, NJ.
-
What is the size of Merck & Co.?
Merck & Co. has 75,000 total employees.
-
What industry is Merck & Co. in?
Merck & Co.’s primary industry is Pharmaceuticals.
-
Is Merck & Co. a private or public company?
Merck & Co. is a Public company.
-
What is Merck & Co.’s stock symbol?
The ticker symbol for Merck & Co. is MRK.
-
What is the current stock price of Merck & Co.?
As of 17-Jun-2025 the stock price of Merck & Co. is $78.28.
-
What is the current market cap of Merck & Co.?
The current market capitalization of Merck & Co. is $197B.
-
What is Merck & Co.’s current revenue?
The trailing twelve month revenue for Merck & Co. is $63.9B.
-
Who are Merck & Co.’s competitors?
GSK, Pfizer (Pharmaceuticals), AstraZeneca, Gilead Sciences, and Bristol-Myers Squibb are some of the 42 competitors of Merck & Co..
-
What is Merck & Co.’s annual earnings per share (EPS)?
Merck & Co.’s EPS for 12 months was $6.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
